PMID- 19235776
OWN - NLM
STAT- MEDLINE
DCOM- 20090507
LR  - 20220408
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 18
IP  - 4
DP  - 2009 Apr
TI  - Risk of community-acquired pneumonia and the use of statins, ace inhibitors and 
      gastric acid suppressants: a population-based case-control study.
PG  - 269-75
LID - 10.1002/pds.1715 [doi]
AB  - PURPOSE: Previous studies have shown that treatment with gastric acid 
      suppressants may be associated with an increased risk of pneumonia whilst the use 
      of statins and ACE inhibitors (ACEI) may decrease the risk of acquiring 
      pneumonia. The evidence is conflicting however. Our aim was to investigate the 
      effect of these drugs on pneumonia using population-based data from the UK. 
      METHODS: We conducted a general population-based case-control study using the 
      health improvement network (THIN), a comprehensive UK general practice database. 
      Conditional multiple logistic regression was used to assess the association 
      between the exposures and pneumonia. RESULTS: After adjusting for potential 
      confounders, a current prescription for statins was associated with a significant 
      reduction in the risk of pneumonia (adjusted OR 0.78, 95% CI 0.65-0.94). 
      Similarly, a current prescription for ACEI was associated with a reduction in the 
      risk of pneumonia (adjusted OR 0.75, 95% CI 0.65-0.86). Contrary to previous 
      study results we did not find a significant association between current 
      prescription for histamine 2 receptor antagonist (H(2)RA) and pneumonia risk 
      (adjusted OR 1.14, 95% CI 0.92-1.40) but current prescriptions for proton pump 
      inhibitors (PPI) were associated with an increased risk of pneumonia (adjusted OR 
      1.55, 95% CI 1.38-1.77). CONCLUSIONS: Statins and ACE inhibitors were associated 
      with a lower risk of pneumonia but these effects were smaller than those observed 
      in previous studies. People prescribed a PPI, but not an H(2)RA at an increased 
      risk of acquiring pneumonia.
FAU - Myles, Puja R
AU  - Myles PR
AD  - Division of Epidemiology & Public Health, University of Nottingham, Clinical 
      Sciences Building, City Hospital, Nottingham NG5 1PB, UK. 
      puja.myles@nottingham.ac.uk
FAU - Hubbard, Richard B
AU  - Hubbard RB
FAU - McKeever, Tricia M
AU  - McKeever TM
FAU - Pogson, Zara
AU  - Pogson Z
FAU - Smith, Christopher J P
AU  - Smith CJ
FAU - Gibson, Jack E
AU  - Gibson JE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Antacids)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Antacids/*adverse effects
MH  - Case-Control Studies
MH  - Community-Acquired Infections/epidemiology/*etiology/prevention & control
MH  - Comorbidity
MH  - Female
MH  - Histamine H2 Antagonists/*adverse effects
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Logistic Models
MH  - Male
MH  - Medical Records Systems, Computerized
MH  - Middle Aged
MH  - Odds Ratio
MH  - Pneumonia/epidemiology/*etiology/prevention & control
MH  - Population Surveillance
MH  - Proton Pump Inhibitors/*adverse effects
MH  - Risk Assessment
MH  - Risk Factors
MH  - United Kingdom/epidemiology
EDAT- 2009/02/25 09:00
MHDA- 2009/05/08 09:00
CRDT- 2009/02/25 09:00
PHST- 2009/02/25 09:00 [entrez]
PHST- 2009/02/25 09:00 [pubmed]
PHST- 2009/05/08 09:00 [medline]
AID - 10.1002/pds.1715 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):269-75. doi: 10.1002/pds.1715.